NCT00979901

Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED)

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Seasonal Allergic Rhinitis--Spring Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,577 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 15 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the ability of montelukast to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine and placebo.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Comparator: montelukast	10 mg montelukast tablet given once daily at bedtime for 2 weeks
DRUG	Comparator: loratadine	10 mg loratadine tablet given once daily at bedtime for 2 weeks
DRUG	Comparator: placebo	placebo tablet given once daily at bedtime for 2 weeks
DRUG	Comparator: montelukast/loratadine	montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks

Timeline

• Start date: 2000-03-01
• Primary completion: 2000-05-01
• Completion: 2000-05-01
• First posted: 2009-09-18
• Last updated: 2022-02-09
• Results posted: 2010-06-08